11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Inhibitors Still Improve Metabolic Phenotype in Male 11β-HSD1 Knockout Mice Suggesting Off-Target Mechanisms

The enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is a target for novel type 2 diabetes and obesity therapies based on the premise that lowering of tissue glucocorticoids will have positive effects on body weight, glycemic control, and insulin sensitivity. An 11β-HSD1 inhibitor (compound...

Descripción completa

Detalles Bibliográficos
Autores principales: Harno, Erika, Cottrell, Elizabeth C., Yu, Alice, DeSchoolmeester, Joanne, Gutierrez, Pablo Morentin, Denn, Mark, Swales, John G., Goldberg, Fred W., Bohlooly-Y, Mohammad, Andersén, Harriet, Wild, Martin J., Turnbull, Andrew V., Leighton, Brendan, White, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2013
Materias:
Energy Balance-Obesity
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4192288/
https://www.ncbi.nlm.nih.gov/pubmed/24169553
http://dx.doi.org/10.1210/en.2013-1613

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4192288/
https://www.ncbi.nlm.nih.gov/pubmed/24169553
http://dx.doi.org/10.1210/en.2013-1613

Ejemplares similares